A discrete-choice experiment to assess patients’preferences for osteoarthritis treatment: an ESCEO working group by Hiligsmann, M. et al.
Seminars in Arthritis and Rheumatism 50 (2020) 859866
Contents lists available at ScienceDirect
Seminars in Arthritis and Rheumatism
journal homepage: www.elsevier.com/locate/semarthritA discrete-choice experiment to assess patients’ preferences for
osteoarthritis treatment: An ESCEO working groupMickael Hiligsmanna,*, Elaine Dennisonb, Charlotte Beaudartc,d, Gabriel Herrero-Beaumonte,
Jaime Brancof, Olivier Bruyereb,c, Philip G Conaghang, Cyrus Cooperb,h, Nasser Al-Daghrii,
Famida Jiwaj, Willem Lemsk, Daniel Pintol, Rene Rizzolim, Thierry Thomasn, Daniel Uebelharto,
Nicolas Veronesep,q, Jean-Yves Reginsterc,d,i
aDepartment of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, P.O. Box 616, 6200, MD, The
Netherlands
bMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
c Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium
dWHO Collaborating Centre for Public Health Aspects of Musculo-Skeletal Health and Aging, Liege, Belgium
eHead of Rheumatology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain
f Rheumatology Department, CEDOC-NOVAMedical School, Faculdade de Ciências Medicas da Universidade Nova de Lisboa, CHLO, Hospital Egas Moniz, Lisbon, Portugal
g Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, UK
hNIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK
i Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, KSA
j Chair of the Committee of Patients Societies at the International Osteoporosis Foundation, Osteoporosis Canada, Toronto, Canada
k Department of Rheumatology, Amsterdam University Medical Center, location VU University Medical Center, Amsterdam, The Netherlands
l Department of Physical Therapy, Marquette University, Milwaukee, USA
m Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Switzerland
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Objective: To evaluate the preferences of patients with osteoarthritis for treatment.
Methods: A discrete-choice experiment was conducted among adult OA patients who were presented with 12
choice sets of two treatment options and asked in each to select the treatment they would prefer. Based on
literature reviews, expert consultation, patient survey and expert meeting, treatment options were charac-
terized by seven attributes: improvement in pain, improvement in walking, ability to manage domestic activ-
ities, ability to manage social activities, improvement in overall energy and well-being, risk of moderate/
severe side effects and impact on disease progression. Random parameters logit model was used to estimate
patients’ preferences and a latent class model was conducted to explore preferences classes.
Results: 253 OA patients from seven European countries were included (74% women; mean age 71.3 years).
For all seven treatment attributes, significant differences were observed between levels. Given the range of
levels of each attribute, the most important treatment attribute in this group was impact on disease progres-
sion (29.5%) followed by walking improvement (17.1%) and pain improvement (16.3%). The latent class
model identified two preference classes. In the first class (probability of 56%), patients valued impact of dis-
ease progression the most (39%). In the second class, walking improvement and improvement in overall
energy and well-being were the most important (23%).
Conclusion: This study suggests that all seven treatment attributes were important for OA patients. Overall,
given the range of levels, the most important outcomes were impact on disease progression and improve-
ment in pain and walking.
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Domestic activities All domestic activities without
difficulty
Some domestic activities with
difficulty
All domestic activities with difficulty
Social activities All social activities without difficulty
Some social activities with difficulty
All social activities with difficulty






Risk of severe side effects 1 patient out of 200 within one year
(0.5%)
1 patient out of 100 within one year
(1%)
1 patient out of 50 within one year
(2%)
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The patient perspective is becoming increasingly important in
clinical and regulatory decision-making [1,2]. Information about
what patients prefer, and how they value various aspects of a health
intervention can be useful when designing, evaluating and imple-
menting healthcare programs [3]. Such insights can also help when
establishing treatment guidelines and should be taken into consider-
ation when designing new drugs or other interventions [4]. There
has therefore been a growing interest in obtaining patients’ preferen-
ces for healthcare interventions. In particular, the use of stated-pref-
erence methods (including discrete-choice experiments (DCE)) has
markedly increased in recent years [5,6]. A DCE is a quantitative
method used to elicit and quantify the preferences of participants [7]
that are asked to repeatedly choose between hypothetical options
that systematically differ in several attributes of interest.
Given the significant challenges and lack of therapeutic options
for osteoarthritis [8], some stated-preference studies have been con-
ducted to elicit preferences for OA treatment [4]. OA is the most com-
mon form of arthritis in later life and most frequently affects the
knee, hand, and/or hip [9]. OA is predominantly characterized by
pain and has been shown to substantially reduce the patient’s mobil-
ity and quality of life and to represent a significant contributor to dis-
ability in the elderly [10]. Currently OA treatments aims primarily to
reduce joint pain, maintain and improve joint mobility and enhance
quality of life. Treatment options (including surgery, pharmacological
and non-pharmacological treatment) may however differ in benefits
and risks, emphasizing the need to assess patients’ preferences for
different aspects of OA treatment [4].
Previous DCEs conducted in OA were mainly conducted to assess
preferences for the characteristics of OA drug treatment suggesting
that DCE is a reliable method in this patient population, but revealed
some contrasting results. Some studies reported that benefit attrib-
utes (e.g. pain improvement, physical improvement) were the most
important for patients [1113], while others suggested that patients
were mainly concerned by side-effects [1416]. However, few stud-
ies have investigated the trade-offs between all potential OA treat-
ment outcomes including impact on pain, physical mobility, joint
structure and side-effects. Further insight into patients’ preferences
for OA patients as well as investigating potential differences in pref-
erences between patients and countries would thus be worthwhile.
The European Society European Society on Clinical and Economic
Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
(ESCEO) has therefore set up a working group to conduct a DCE to
further elicit patients’ preferences in OA across European countries.
The aim of this study was therefore to assess the preferences of
European patients for OA treatment outcomes using a DCE. Further-
more, as secondary objectives, we aimed to assess heterogeneity in
responses by determining different preference profiles of participants
and revealing potential differences in preferences between the par-
ticipating European countries.
Methods
A DCE was used to examine patients preferences for OA treat-
ment. In the DCE survey, patients were presented with a series of
choices and asked in each to select the treatment (Treatment A and
Treatment B) they would prefer. The two hypothetical treatments
were described by a set of attributes which were further specified by
attributes` levels (see below). Good research practices for stated-pref-
erence studies were followed [3,17].
Attributes and levels
The identification and prioritization of important OA treatment
attributes was conducted following a 4-stage process: (1) twoscoping reviews (i.e. an exhaustive review of preference studies in
OA, and a review of outcomes in RCTs of OA treatment) to generate
an initial list of OA treatment outcomes; (2) interviews with OA
patients (n=20) to identify any missing outcomes and an expert con-
sultation (n=17) to review and validate initial outcomes; (3) a patient
survey (n=56) with OA patients from Belgium, Italy, Portugal, Nether-
lands, Switzerland and the United Kingdom to rank the most impor-
tant outcomes; (4) an expert meeting including one OA patient
(n=17) to identify the most important OA treatment outcomes for
inclusion in the DCE based on the survey results, and to select levels
for each chosen outcome. More details about the findings of each
stage are presented in Appendix A. Finally, the following seven attrib-
utes were included: improvement in pain, improvement in walking,
ability to manage domestic activities, ability to manage social activi-
ties, improvement in overall energy and well-being, risk of moder-
ate/severe side effects and impact on disease progression (see
Table 1). For each attribute, three or four levels were agreed upon by
the expert group.
Experimental design
A main-effect efficient design by maximizing the D-efficiency was
used to select the subset of choice sets to be presented to the patients
using Ngene software (Version 1.1.1, http://www.choice-metrics.
com). A total of 24 choice tasks was designed and blocked into two
versions of the questionnaire containing 12 choice tasks each. A dom-
inance test - a choice set with one hypothetical treatment that is
clearly better than the other (i.e. a treatment associated with higher
improvement in pain, walking and overall energy, better ability to
conduct domestic and social activities, similar side-effects risk and
lower impact on disease progression), - was added to assess reliabil-
ity of respondents’ choices [18]. Each respondent therefore received
13 choice tasks. An example of a choice task is shown in Fig. 1. All
choice tasks for one version of the questionnaire are available on
Appendix B (the dominance test is the choice task number 10).
Fig. 1. Example choice set of the DCE questionnaire.
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OA patients and experts suggested that participants would be willing
to trade-off between hypothetical treatment options, further being
not directly connected to drug options. To avoid larger numbers of
respondents who choose the opt-out option to prevent additional
loss of power, we therefore decided to use binary choices and thus
forced a choice.
Questionnaire design
The questionnaire was paper-based. The attributes and levels
were first described, and an example of a completed choice task was
included. After respondents had completed the 13 choice tasks, they
were asked how difficult they found the tasks on a seven-point Likert
scale. Data on participants’ demographics and socioeconomic (i.e.
age, education, gender, and education) and some medical characteris-
tics (i.e. knee and/or hip OA, treatment for OA, hip/knee replacement)
were also collected.
The questionnaire was developed in English by MH and ED, and
reviewed and approved by the ESCEO working group (n=17). The work-
ing group consisted of clinical scientists in the field of OA and DCE
experts who were selected by the Scientific Advisory Board of ESCEO.
The English version of the questionnaire was then pilot tested with
some clinicians and 20 OA patients to check interpretation problems,
face validity and the length of the questionnaire. Only minor changes to
layout were made. The questionnaire was then translated into addi-
tional languages (French, Spanish, German and Italian), covering the lan-
guages spoken across the countries in our sample. Each language
version was checked and approved by at least one additional native
speaker. One version of the questionnaire is available in Appendix B.
Study population, data collection and sample size
The study was conducted in seven European countries including
Belgium, France, Italy, the Netherlands, Portugal, Spain and United
Kingdom between May 2018 and July 2019. The DCE was conductedin OA patients that were recruited during specialist outpatient clinics
or from cohort studies. Participants who were not cognitively able to
understand and fill out the questionnaire or lacked understanding of
local language were excluded. The questionnaire was completed by
the participant at the clinic or at home. In the latter case, it was
returned in a postage-paid envelope. Sample size calculation for
stated-preference studies is difficult as it depends on the true values
of the unknown parameters estimated in the DCE. Hence, a minimum
of 200 respondents was targeted for the whole sample, which was
sufficient based on common rules-of-thumb for minimum sample
size [19] and similar to other DCEs [6].
Ethics approval
Approval for this study was obtained from the Medical Ethics
Committee of the University of Liege that coordinated the project.
Participants gave informed written consent. Additional local ethics
approval was obtained at those participating centers that required
ethics approval for a DCE questionnaire study.
Statistical analyses
Data analysis was carried out using Nlogit software, version 5.0.
Data of participants who failed the dominance test were excluded.
The available patient data were analysed with various recommended
statistical methods [17].
First, a random parameters logit model was used which allows to
capture heterogeneity by estimating the standard deviation of the
parameter’s distribution. The model provides mean coefficients as
well as a measure of the distribution around the mean coefficient in
the form of a standard deviation. If the standard deviation is signifi-
cantly different from zero, this is interpreted as evidence of signifi-
cant preference heterogeneity for the attribute/level in the sample.
We used a panel model to account for the panel nature of the data, as
each participant completed 12 choice sets. To take scale heterogene-
ity into account, which relates to potential differences between
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uted random component was added for each country.
All variables were included as effects-coded categorical variables
that we assumed to be normally distributed. The model was estimated
by using 1,000 Halton draws and no interaction terms were included.
Using effect coding, mean attributes are normalized to zero and prefer-
ence weights are relative to the mean effect of the different levels of the
attribute. The sign of a coefficient reflects whether an attribute level
leads to an increase (positive) or a decrease (negative) on the patients’
utility. The value of each coefficient represents the importance patients
assign to an attribute level. P-values represent the statistical difference
between the preference weight of the attribute levels and the mean
effect of the same attribute [17]. If the 95% confidence interval around
two levels did not overlap, the differences between the preference
weights were considered as statistically different. A priori, we expected
that the attribute levels with large improvements, heightened ability to
conduct activities, lower risk of side-effects and improvement in joint
structure would have a positive effect on utility (i.e. a positive sign).
Preferences estimate from the model was then used to calculate
the conditional relative importance of attributes overall and per
country. Using the range method [17], the range of attribute-specific
levels is calculated by measuring the difference between the highest
and lowest coefficient for the levels of the respective attribute. The
conditional relative importance is then calculated by dividing the
attribute-specific level range by the sum of all attribute level ranges.
The relative attribute importance calculated with this method always
depends on the range of levels chosen per attribute and on the other
attributes included in the experiment. Given the large effect of the
level “severe degradation”, we also estimated the conditional relative
importance by excluding this level.
Second, a latent class model was used to determine preference
classes. Latent class models allow to identify the existence and num-
ber of classes in the population based on their treatment preferences
[20]. To determine the number of classes, we selected the model with
the best fit based on the Akaike information criterion. The association
between selected patient characteristics and latent class membership
was then determined using a multivariable logistic regression model.
The multivariable model was considered exploratory and was limited
to the variables with different probability between latent classes.
This analysis was conducted with IBM SPSS 24TM.
Results
Participants’ characteristics
A total of 285 questionnaires were completed and returned. Of
those, 32 participants failed the dominance test and were excluded
from the final analysis. Participants who failed the dominance testTable 2
Patients’ characteristics.
Belgium France Italy N
Failed dominance test 5 5 5 0
N included 47 31 45 15
Age, mean, years 74.3 (8.9) 64.8 (9.7) 77.6 (12.5) 68
Female gender 73% 52% 86% 67
Knee OA 47% 68% 13% 73
Hip OA 17% 16% 7% 0%
Knee and hip OA 34% 7% 7% 13
Treatment OA 43% 64% 19% 33
Hip/knee replacement 28% 13% 10% 20
Education
Primary 4% 10% 73% 0%
Some high 40% 38% 14% 33
Secondary 21% 24% 7% 20
College or University 34% 27% 7% 47
Difficulty 3.8 4.1 5.2 3.did not differ in age, gender and education level from those who
passed, and inclusion of these patients in an additional analysis did
not affect the results and conclusions. The final sample consisted of
253 participants (47 from Belgium, 31 from France, 45 from Italy, 15
from the Netherlands, 42 from Portugal, 51 from Spain, 22 from
United Kingdom). The respondents had a mean age of 71.3 years, and
74% were female. Sample characteristics are shown in Table 2.
Patients had mainly lower extremely OA (93%), with 57%, 14% and
21% of patients reporting having knee OA, hip OA and both knee and
hip OA, respectively. On average, the task difficulty was seen as mod-
erate with an average score of 4.1, based on responses to a seven-
point scale (one for extremely easy and seven for extremely difficult).
Patients’ preference
The random parameters logit model results are presented in Table 3
and Fig. 2. In all seven selected OA treatment outcomes, significant dif-
ferences were observed between levels (as the 95% CI did not overlap),
meaning that all attributes are important for patients. All relationships
were in the expected direction, as improved levels for each attribute
were associated with higher coefficients (by example, 0.63 for no
pain improvement, 0.22 for mild pain improvement, 0.25 for moder-
ate pain improvement and 0.61 for large pain improvement). Patients
preferred thus a treatment with greater improvement in pain, walking
and/or energy, heightened ability to conduct social and domestic activ-
ities, lower risk of side-effects, and lower structural progression. As
previously mentioned, each coefficient is estimated relative to the
mean attribute effect. As example, the negative coefficient of mild
improvement in pain means therefore that this level has a lower effect
on utility than the average effect of the related attribute.
Overall, given the range of levels of each attribute, the most impor-
tant treatment attribute OA patient reported was impact on disease
progression (29.5%) followed by walking improvement (17.1%), pain
improvement (16.3%), ability to conduct domestic activities (11.5%),
improvement in energy and well-being (10.2%), ability to conduct
social activities (8.2%) and risk of severe side-effects (7.4%). When
excluding the level ‘severe degradation’ for the calculation of the rela-
tive importance, the conditional relative importance of the impact on
disease progression was only 12%. Given the significant standard devi-
ation for at least one level per attribute, variations in preferences
between participants were thus observed for all attributes, and were
especially marked for impact on disease progression (see Table 3).
The conditional relative importance of attributes per country is
shown in Appendix C. Given the range of levels of each attribute, the
impact on disease progression was the most important OA treatment
outcome in all countries except in Italy where pain improvement was
the most important outcome. In all countries, significant differences
between levels for all seven OA treatment outcomes were observed.ether. Portugal Spain UK Overall
9 4 4 32
42 51 22 253
.1 (4.2) 66.4 (11.6) 67.2 (11.2) 81.8 (2.9) 71.3 (11.6)
% 88% 80% 55% 74%
% 36% 96% 32% 57%
10% 0% 58% 14%
% 50% 0% 10% 21%
% 83% 68% 67% 54%
% 15% 12% 64% 20%
57% 18% 23% 30%
% 14% 20% 46% 27%
% 14% 31% 4% 18%
% 10% 31% 27% 23%
6 3.4 3.8 4.5 4.1
Table 3
Results from the random parameters logit model.
Attributes and levels Estimate (95% CI) a Standard deviation b Conditional relative importance
(without the level ‘severe degradation’)
Pain improvement 16.3% (20.4%)
None 0.63 (0.84, 0.42)*** 
Mild 0.22 (0.38, 0.07)** 0.39 (0.18, 0.60)***
Moderate 0.25 (0.10, 0.39)*** 0.22 (0.08, 0.53)
Large 0.61 (0.42, 0.80)*** 0.69 (0.49, 0.89)***
Walking improvement 17.1% (21.3%)
None 0.59 (0.77, 0.41)*** 
Mild 0.18 (0.33, 0.03)** 0.42 (0.25, 0.60)***
Moderate 0.06 (0.08, 0.19) 0.10 (0.21, 0.40)
Large 0.71 (0.53, 0.89)*** 0.21 (0.06, 0.42)
Domestic activities 11.5% (14.3%)
All domestic activities with difficulty 0.31 (0.48, 0.14)*** 
Some domestic activities with difficulty 0.26 (0.37, 0.14)*** 0.27 (0.08, 0.45)***
All domestic activities without difficulty 0.56 (0.41, 0.72)*** 0.16 (0.05, 0.37)
Social activities 8.2% (10.2%)
All social activities with difficulty 0.26 (0.45, 0.08)** 
Some social activities with difficulty 0.09 (0.21, 0.03)* 0.29 (0.13, 0.45)***
All social activities without difficulty 0.36 (0.19, 0.52)*** 0.29 (0.03, 0.55)***
Overall energy and well-being improvement 10.1% (12.5%)
None 0.31 (0.45, 0.18)*** 
Mild 0.05 (0.19,0.10) 0.29 (0.07, 0.50)***
Moderate 0.09 (0.23, 0.04) 0.14 (0.15, 0.44)
Large 0.45 (0.27, 0.63)*** 0.34 (0.12, 0.55)
Risk of severe side-effects 7.4% (9.3%)
1 patient out of 200 within 1 year (0.5%) 0.30 (0.14, 0.45)*** 0.39 (0.23-0.54)***
1 patient out of 100 within 1 year (1%) 0.03 (0.14, 0.09) 0.16 (0.02, 0.33)
1 patient out of 50 within 1 year (2%) 0.24 (0.40, 0.09)*** 
Impact on disease progression 29.5% (11.9%)
Severe degradation 1.61 (1.81, 1.22)*** 
Mild degradation 0.18 (0.02, 0.34)** 0.93 (0.67, 1.18)***
No degradation 0.61 (0.43, 0.80)*** 0.84 (0.64, 1.04)***
Improvement in joint structure 0.72 (0.50, 0.94)*** 0.60 (0.39, 0.80)***
a Given the use of effects coding, the reported results for each of the attribute levels indicate the distance from average utility derived from a
specific attribute. A positive (negative) sign for a given level indicates a level has a positive (negative) effect on utility compared to the mean
effect of the attribute
b Standard deviations correspond to the random component of the model coefficients,
** P<0.05,
*** P<0.01
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The latent class model identified two preferences classes with
class probabilities of 56% and 44%, respectively (see Table 4). In theTable 4
Latent class analysis and association between patients’ characteri
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Knee OA 54% 63
Hip OA 16% 10
Knee and hip OA 26% 13
Treatment OA 62% 43
Hip/knee replacement 21% 20first class (probability of 56%), participants valued impact of disease
progression the most (39%), and the other attributes had a score of
conditional relative importance between 5% and 14%. In the second
class, walking improvement and improvement in overall energy andstics and latent class membership.
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Fig. 2. Patients’ preferences estimates.
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importance of 23%), while impact on disease progression was the sec-
ond last attribute.
Patients from Belgium, Portugal and France were more likely to be
in the class concerned mainly by the impact on disease progression.
Women, patients with hip OA and patients with OA treatment were
also more likely to be in this group. The multivariable logit model
revealed three significant results: patients from France and women
were significantly more frequent in the class concerned by impact on
disease progression and patients from Italy more often in the class
with a focus on walking and overall energy. At a significance level of
10% only, patients with knee OA were also more likely to be in the
class with walking and energy improvement.
Discussion
This study demonstrates that, on average, all the seven treatment
attributes we selected were important for OA patients. Overall, given
the range of levels included in our experiment, the most important
outcomes to patients were impact on disease progression and
improvement in pain and walking, although variations in preferences
were observed between patients and countries. Two preference clas-
ses were identified in the latent class analysis: one with a stronger
emphasis on disease progression, and the other on walking and pain
improvement.
Overall, the conditional relative importance stated was the most
important for the impact on disease progression. This finding should
however be interpreted with great caution as the relative importanceof the attributes is based on the range between the highest and low-
est coefficient for the levels of the respective attribute. A level ‘severe
degradation’ was included and was associated with a strong negative
preference. Excluding this level in the calculation of the relative
importance of disease progression (i.e. estimating a difference
between mild degradation and improvement in joint structure)
placed the impact on disease progression as the second least impor-
tant attribute only.
Although the levels for the risk of severe side-effects were signifi-
cantly different and thus important, side-effects were less important
than treatment benefits. This finding is in contrast to the study of
Hauber et al. [21] where the risk of side-effects expressed as heart-
attack or stroke risk were considered more important than benefits
in ambulatory pain and doing domestic activities. The framing of spe-
cific side-effects could potentially be more sensitive for patients than
a general description of moderate/severe side-effects. In the latent
class analysis, patients from France and women were significantly
more likely to be in the class concerned mainly by the impact on dis-
ease progression, while patients from Italy were more likely in the
second latent class concerned by improvement in walking and overall
energy.
This study could have implications for research, clinical and regu-
latory decisions. Our study reinforces the need to develop treatment
that could influence joint structure. OA remains an unmet medical
need and some treatments have been developed but failed to develop
joint structure-modifying treatments for OA [22]. As current treat-
ment options (including surgery, pharmacological and non-pharma-
cological treatment) may differ in benefits and risks, assessing
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help to improve disease management. The findings of this study
highlight the importance of investigating individual preferences and
incorporating them in a shared-decision making process.
Although this study followed good research practices, some
potential limitations exist. First, some participants who were not cog-
nitively able to fill out and understand the questionnaire were
excluded. Our sample could thus be slightly “over-educated” com-
pared to the average OA patient. In addition, our patients were
mainly recruited from specialist outpatient clinics and thus may not
be representative of all OA patients visiting general practitioners. We
also do not have information about howmany patients were not cog-
nitively able to understand the questionnaire or fill them in. Thus,
selection bias and limitations in generalizability of our results cannot
be excluded. Further, patients in our study had mainly lower
extremely OA (at the hip and/or knee) and preferences for OA treat-
ment may be different for hand or shoulder OA and would thus
require further investigation. In addition, the sample size was lower
in some countries and, although significance was observed in each
country, a higher sample size would be needed to confirm findings
per country. The sample size was targeted for the whole sample and
not for individual country to reveal potential differences between
countries. In our study, we therefore pooled data from all countries
which could be a potential limitation. Second, although sound meth-
odology was used to select and define attributes including large
patient involvement, it is possible that additional attributes may play
a role, at least in some countries or for some patients. In particular,
costs could be an important attribute in countries/populations where
patients have an out-of-pocket contribution. The cost attribute did
not emerge as an important attribute in our survey that mainly
included patients aged over 65 years that do not have to pay for
drugs. To avoid presenting a cost attribute that would have not been
relevant for most patients, we therefore agreed to not include a cost
attribute in the DCE. Similarly, mode of administration was not con-
sidered as an important attribute in our preliminary survey and,
given the constraint to limit the number of attributes, mode of
administration was not included in our list of attributes that already
contained seven characteristics. We however acknowledge that some
patients may have preferences for route of administration [23] (topi-
cal vs oral vs injection) and this would require further investigation.
To maintain consistency across countries, the same list of attributes
as well as levels and the same design was used in all countries. Third,
although the working group did not consider some combinations of
levels as implausible, some could not be expected at first glance (by
example being able to have all domestic activities with difficulty and
a severe impact on disease progression but all social activities with-
out difficulty). To avoid decreasing design efficiency, the working
group agreed to not include implausible combinations in the design.
The pilot test with about 20 OA patients further did not reveal any
problems with the task. Fourth, back and forward translations of the
questionnaire were not performed, and a pilot study was not con-
ducted in all countries. Finally, while DCEs are widely used, an inher-
ent limitation is that respondents are evaluating hypothetical
options. Therefore, what respondents declare they will do may differ
from what they would actually do if faced with the choice in real life.
Conclusion
This study suggests that all seven treatment attributes selected
were important for OA patients. Overall, the most important out-
comes to OA patients were the impact on disease progression and
improvement in pain and walking, although variations in preferences
were observed between patients. Excluding the level “severe degra-
dation” in the calculation of the conditional relative importance sub-
stantially decreases the relative importance of the impact on disease
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